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Abstract
Neurotensin (NT), a gastrointestinal hormone, binds its
receptor [neurotensin receptor (NTR)] to regulate the
growth of normal and neoplastic intestinal cells;
molecular mechanisms remain largely undefined. Gly-
cogen synthase kinase-3 (GSK-3) regulates diverse
cellular processes, including cell growth and apop-
tosis. Here, we show that NT induces the phosphor-
ylation of GSK-3A/B in the human colon cancer cell line
HT29, HCT116, or SW480, which possesses high-
affinity NTR. The effect of NT was blocked by inhibitors
of protein kinase C (PKC), but not by inhibitors of
mitogen-activated protein kinase/extracellular signal-
regulated kinase (MEK1) or phosphatidylinositol-3 ki-
nase, suggesting a predominant role for PKC in GSK-3b
phosphorylation by NT. Pretreatment with Go¨6976
(which inhibits PKCa and PKCb1) or downregulation
of endogenous PKCa or PKCb1 blocked NT-mediated
GSK-3b (but not GSK-3a) phosphorylation. Moreover,
a selective PKCb inhibitor, LY379196, reduced NT-
mediated GSK-3b (but not GSK-3a) phosphorylation,
suggesting a role for PKCb1 in the NT-mediated
phosphorylation of GSK-3b and an undefined kinase
in the NT-mediated phosphorylation of GSK-3a. Treat-
ment with NT or the GSK-3 inhibitor SB216763 in-
creased the expression of cyclin D1, a downstream
effector protein of GSK-3 and a critical protein for the
proliferation of various cells. Our results indicate that
NT uses PKC-dependent pathways to modulate GSK-3,
which may play a role in the NT regulation of intestinal
cell growth.
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Introduction
Regulatory hormones, which are localized to specialized
endocrine cells in the small bowel, control numerous phys-
iological functions of the gastrointestinal (GI) tract, including
secretion, motility, and mucosal growth [1]. The gut peptide
neurotensin (NT), a tridecapeptide localized to entero-
endocrine cells of the distal small bowel [2,3], facilitates
fatty acid translocation [4], affects gut motility [5], and
stimulates the growth of normal gut mucosa [6,7]. In addition
to its trophic effects on normal GI tissues, NT stimulates the
proliferation of certain pancreatic, colonic, and prostatic
cancers bearing high-affinity neurotensin receptors (NTRs)
[8]. NTR and its mRNA are expressed in many human colon
cancer cell lines and primary colorectal cancers [9]. Therefore, it
is important to characterize NT-mediated signal transduction
pathways in human colon cancer cells, which may identify
potential targets for therapeutic interventions.
Previously, we have shown that NTactivates the extracellular
signal-regulated kinase (ERK) pathway in human colon and
pancreatic cancer cells [10,11]. In agreement with our studies,
other investigators have demonstrated that NTactivates ERK in
colonic adenocarcinoma cells [12], colonic epithelial cells [13],
and pancreatic cancer cells [14]. NT-stimulated ERK activation is
dependent on Ras and is involved in NT-induced IL-8 expression
[13]. NT-mediated stimulation of IL-8 gene expression involves a
nuclear factor nB–dependent pathway [13]. In addition to the
activation of ERK, NT induces the activation of protein kinase C
(PKC) and phosphatidylinositol-3 kinase (PI3-kinase)/Akt in
some cells [15–17]. NT plays an important role in the stimula-
tion of intestinal cell proliferation; however, the signal pathways
mediated by NTare largely undefined.
PKC, particularly the PKCa and PKCb1 isoforms, has been
shown to phosphorylate glycogen synthase kinase (GSK) 3a
and GSK-3b [18,19]. PKC is ubiquitously expressed and in-
volved in diverse cellular functions, such as the potentiation
of the proliferative response to G protein–coupled receptor
agonists [20–22]. NT stimulates the formation of inositol tri-
sphosphate [1,4,5], increases intracellular calcium [23,24], and
activates PKC [25]. However, the functional effects of PKC-
mediated NTsignaling are not known.
GSK-3 is an evolutionarily conserved signalingmolecule that
plays an important role in diverse biologic processes [26]. More
recent studies indicate a role for GSK-3 in the control of cell
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proliferation and survival in mammalian cells and in the
identification of GSK-3 as a component of the Wnt signaling
pathway, which controls development in invertebrates and
vertebrates [27–29]. GSK-3 phosphorylates cyclin D1,
resulting in its degradation [30,31]. Two isoforms of GSK-3,
GSK-3a and GSK-3b, have been identified [32]. Both iso-
forms are phosphorylated at Ser-21 in GSK-3a and at Ser-9
in GSK-3b [26], resulting in the inhibition of enzymes. Al-
though studies have focused primarily on GSK-3b, GSK-3a
has similar (but not identical) biochemical properties [26,33].
Several kinases have been shown to phosphorylate these
inhibitory sites in vitro [26]. Protein kinase B (PKB/Akt), a
serine/threonine kinase located downstream of PI3-
kinase, phosphorylates both of these sites in vitro and in vivo
[34], suggesting that certain growth factors repress GSK-3
activity through the PI3-kinase–PKB/Akt signaling cascade.
In addition, p90RSK, a downstream target of the MEK/ERK
pathway, and certain PKC isoforms have been shown to phos-
phorylate and inactivate both isoforms of GSK-3 [19,35].
These findings suggest that GSK-3 represents an important
convergence point that integrates signals from multiple
signaling cascades.
In our current study, we show that NT stimulates GSK-3
phosphorylation in human colon cancer cells that possess the
high-affinity NTR through an intracellular signaling pathway
involving PKC, independent of previously identified PI3-
kinase–PKB/Akt and MEK/ERK pathways. These results
indicate that, depending on the stimulatory context, the
activity of GSK-3 can be regulated through multiple signaling
mechanisms. Moreover, the NT-stimulated induction of cell
growth noted in NTR+ colon cancers may be mediated, in
part, through PKC-dependent GSK-3 inhibition.
Materials and Methods
Materials
GF109203x, Ro-318220, PD98059, and Go¨6976 were
provided by Calbiochem (La Jolla, CA). LY319796 was a
generous gift from Eli Lilly Co. (Indianapolis, IN). The GSK-3
inhibitor SB-216763 was purchased from Tocris (Ellisville,
MO). Rabbit anti–phospho-GSK-3a/b (Ser-21 and Ser-9),
rabbit anti–phospho-Akt, and rabbit anti-Akt antibodies were
purchased from Cell Signaling (Beverly, MA). Mouse mono-
clonal anti–GSK-3 (clone 4G-1E) and secondary antibodies
were obtained fromUpstate Biotechnology (LakePlacid, NY).
Phorbol-12-myristate-13 acetate (PMA), wortmannin, NT,
myelin basic protein (MBP), and rabbit anti–b-actin antibody
were from Sigma (Solon, OH). Mouse anti–phospho-ERK1/
2, rabbit anti-ERK1, rabbit anti-PKCa, rabbit anti-PKCb1, and
rabbit anti–cyclin D1 antibodies were from Santa Cruz Bio-
technology (Santa Cruz, CA). [g-32P] adenosine triphosphate
(ATP) was obtained from PerkinElmer Life Sciences (Boston,
MA). The enhanced chemiluminescence (ECL) system for
Western immunoblot analysis and protein A-Sepharose was
from Amersham Biosciences (Piscataway, NJ). The concen-
trated protein assay dye reagent was from Bio-Rad Labora-
tories (Hercules, CA). Tissue culture media and reagents
were from Invitrogen (Carlsbad, CA). All other reagents were
of molecular biology grade and were from Sigma.
Cell Culture
The human colon cancer cell lines HT29, HCT116, and
SW480 were obtained from the American Type Culture
Collection (Manassas, VA). HT29 and HCT116 cells were
grown in McCoy’s 5A supplemented with 10% fetal bovine
serum (FBS). SW480 cells were grown in RPMI 1640 sup-
plemented 10% FBS. Before stimulation with NT, cells were
grown to subconfluence in 60-mm dishes and starved in
serum-free medium for 24 hours, unless otherwise indicated.
Western Blot Analysis
Total protein (100 mg) was resolved on a 10% polyacryl-
amide gel and transferred to polyvinylidene difluoride (PVDF)
membranes. Filters were incubated for 1 hour at room
temperature in a blotting solution. Phospho-GSK-3a/b,
GSK-3, cyclin D1, PKCa, PKCb1, and actin were detected
with specific antibodies following blotting with a horseradish
peroxidase–conjugated secondary antibody and were visu-
alized using an ECL detection system.
In Vitro Kinase Assays
PKCa or PKCb1 activity was determined in cell extracts,
as described previously [36]. Briefly, total PKCa or PKCb1
was determined by measuring the incorporation of 32P into
MBP. Extracts from HT29 cells treated with or without NT
were incubated with PKCa or PKCb1 antibody overnight and
with protein A beads for 3 hours at 4jC by gentle rocking.
Immunocomplexed beads were washed twice with cell lysis
buffer and twice with kinase buffer (25 mM Tris, pH 7.4; 2 mM
dithiothreitol; 0.1 mM Na3VO4; 10 mM MgCl2; and 5 mCi of
[g-32P]ATP). Immunocomplexes were resuspended in 40 ml
of kinase buffer supplemented with 10 mM ATP and 5 mg of
MBP and incubated for 30 minutes at 30jC. Kinase reac-
tions were terminated with a sodium dodecyl sulfate (SDS)
sample buffer. Samples were size-fractionated by SDS poly-
acrylamide gel electrophoresis (PAGE), and 32P-labeled
MBP was quantified autoradiographically after fixing and
drying the gel.
Results
NT Induces the Phosphorylation of GSK-3a/
GSK-3 not only functions as a regulator of metabolism but
also plays a critical role in the signal transduction of many
growth factors such as IGF-1, insulin, and neuronal growth
factor [26]. To assesswhetherGSK-3 isalso regulatedbyNT, a
GI hormone that binds its receptor to regulate the proliferation
of normal and neoplastic intestinal cells [8], we treated HT29
cells, a human colon cancer cell line that possesses high-
affinity NTR [9], with different concentrations of NT. Phos-
phorylation of GSK-3 was determined by immunoblotting with
a GSK-3 phospho-specific antibody that recognizes GSK-3a
phosphorylated at Ser-21 and GSK-3b phosphorylated at
Ser-9 (Figure 1). NT treatment induced a dosage-dependent
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(Figure 1A) and time-dependent (Figure 1B) phosphorylation
of GSK-3a and GSK-3b at the respective serine residues. The
effect of NT on GSK-3 was noted at a dosage of 5 nM and
reached a maximum at 100 nM.
NT Induces Signaling Pathways That May Mediate
the Induction of GSK-3a/ Phosphorylation
Several serine/threonine kinases, including PI3-kinase/
Akt [34], p90RSK [37], a downstream target of MEK/ERK,
and some PKC isoforms [18,19], have been shown to phos-
phorylate and inhibit GSK-3 in vitro. A number of studies
suggest that ERK, PKC [12–14], and PI3-kinase/Akt path-
ways are involved in NT signaling in certain cells [15,16,
23,38]. In addition, NT-induced MAP kinase activation can
be attenuated by the PKC inhibitor GF109203x [12]. There-
fore, we measured ERK1/2 and Akt activity by Western blot
analysis using anti–phospho-ERK1/2 or anti–phospho-Akt
antibody, and PKCa and PKCb1 activity by an immuno-
complex kinase assay, after treating HT29 cells with NT
for various times. As shown in Figure 2A, treatment with
NT increased ERK1/2 and Akt phosphorylation in a time-
dependent fashion in HT29 cells, suggesting the activation of
ERK1/2 and Akt by NT. In vitro kinase assay showed that
PKCa and PKCb1 activity increased at 5 minutes after NT
treatment. As a positive control, PMA induced PKCb1 activity
in HT29 cells (Figure 2B). Our results demonstrate the
activation of ERK1/2, Akt, PKCa, and PKCb by NT; any of
these pathways may mediate NT-induced GSK-3 phosphor-
ylation in HT29 cells.
NT Induces GSK-3 Phosphorylation through
PKC Activation
We next examined the involvement of these kinases in
the NT-induced phosphorylation of GSK-3 (Figure 3). Cells
were pretreated with inhibitors to MEK (PD98059), PKC
(Ro-318220 and GF109203x), or PI3-kinase (wortmannin)
Figure 1. Treatment with NT inducesGSK-3a/ phosphorylation in HT29 cells.
HT29 cells were serum-starved for 24 hours, followed by treatment with
different concentrations of NT (A) for 20 minutes or NT (100 nM) over a time
course (B). Total protein was extracted from cells and resolved by SDS-PAGE,
transferred to PVDF membranes, and probed with anti –phospho-GSK-3a/
antibody; membranes were stripped and reprobed with anti –GSK-3a/ anti-
body. Representative data from five separate experiments are shown.
Figure 3. Inhibition of PKC, but not of MEK or PI3-kinase, blocks NT-
stimulated GSK-3 (but not GSK-3a) phosphorylation. (A) HT29 cells were
serum-starved for 24 hours. Cells were pretreated with or without the MEK1
inhibitor PD98059 (40 M), PKC inhibitors Ro-318220 (2 M) and
GF109203x (2 M), or the PI3-kinase inhibitor wortmannin (200 nM) for
30 minutes, followed by treatment with NT (100 nM) alone or in combination
with the inhibitors. After 20 minutes of treatment, total protein was extracted
from cells and resolved by SDS-PAGE, transferred to PVDF membranes, and
probed with anti –phospho-GSK-3a/ antibody. Membranes were stripped
and reprobed with anti –GSK-3a/. Representative data from three separate
experiments are shown.
Figure 2. Treatment with NT increases ERK1/2, Akt, PKCa, and PKC1
activity in HT29 cells. HT29 cells were serum-starved for 24 hours, followed by
treatment with NT (100 nM) for various times. (A) Total protein was extracted
from cells and resolved by SDS-PAGE, transferred to PVDF membranes, and
probed with anti –phospho-ERK1/2 or anti –phospho-Akt antibody; mem-
branes were stripped and reprobed with anti –ERK1/2 or Akt antibody,
respectively. (B) Total protein was immunoprecipitated (IP) with either anti-
PKCa or PKC1 antibody, and resultant immune complexes were analyzed for
PKCa or PKC1 activity using MBP as substrate. Signals from three separate
experiments were quantitated densitometrically and expressed in relation to
PKCa or PKC1 activity (corrected for control p-MBP). HT29 cells were treated
with PMA (100 nM) for 10 minutes, and PKC1 activity was assayed using
MBP as substrate.
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for 30 minutes before stimulation with NT (100 nM). GSK-3
phosphorylation was analyzed by Western blot analysis
(Figure 3). As expected, treatment with NT increased the
phosphorylation of both GSK-3a and GSK-3b (lane 6). Inter-
estingly, NT-mediated phosphorylation of GSK-3b, but not
GSK-3a, was completely blocked by treatment with Ro-
318220 (lane 3) orGF109203x (lane 4). In contrast, treatment
with PD98059 or wortmannin did not block either GSK-3a or
GSK-3b phosphorylation by NT (lanes 2 and 5). Collectively,
these results suggest a role for the PKC pathway, but not
for MEK/ERK or PI3-kinase, in the NT-induced phosphoryla-
tion of GSK-3b.
To examine the specific isoforms of PKC involved in
mediating NT signaling to GSK-3, we determined whether
NT-induced GSK-3 phosphorylation is blocked by the con-
ventional PKC inhibitor Go¨6976 (which inhibits PKCa and
PKCb1). HT29 cells were pretreated with Go¨6976 for 30 min-
utes before stimulation with NT, and GSK-3 phosphorylation
was visualized by Western blot analysis. Pretreatment with
Go¨6976 blocked NT-mediated GSK-3b phosphorylation in a
dose-dependent fashion (Figure 4A). The role of PKCa and
PKCb1 was further examined in cells treated with or without
1 mM PMA for 24 hours to downregulate these enzymes
(Figure 4, B and C). Treatment with PMA (1 mM) for 24 hours
significantly reduced the basal expression of PKCa and
PKCb1 (Figure 4B). To address the potential role of these
proteins in the induction of GSK-3 phosphorylation by NT,
HT29 cells were treated with PMA (1 mM) for 24 hours,
followed by the addition of NT (100 nM) for 20 minutes.
GSK-3 phosphorylation was determined by Western blot
analysis (Figure 4C). In agreement with changes in PKCa
and PKCb1 levels, the phosphorylation of GSK-3b, but not
GSK-3a, was abolished by chronic PMA treatment, further
suggesting a role for PKCa or PKCb1 in the NT-mediated
phosphorylation of GSK-3b.
To further examine the specific isoforms of PKC involved
in mediating NT signaling to GSK-3, we used LY379196, a
currently available potent and selective PKCb inhibitor with
an IC50 = 30–50 nM for PKCb [39,40], to examine the role of
a single classic PKC isozyme, PKCb1. Pretreatment with
LY379196 completely blocked NT-mediated GSK-3b (but
not GSK-3a) phosphorylation (Figure 4D). These results
suggest a role for PKCb1 in theNT-mediated phosphorylation
of GSK-3b and for an undefined kinase that may be respon-
sible for the NT-induced phosphorylation of GSK-3a.
NT-Mediated GSK-3a/ Phosphorylation Occurs
in Other Human Colon Cancer Cell Lines with NTR
We have shown that NT induces GSK-3 phosphorylation
in the HT29 human colon cancer cell line. To determine
whether this induction is limited to HT29 cells or occurs in
other colon cancer cells expressing the high-affinity NTR,
SW480 and HCT116 cells were treated with NT (100 nM) for
20 minutes. Total protein was extracted, and Western blot
analysis was performed. As shown in Figure 5, NT induced
GSK-3a/b phosphorylation in SW480 (Figure 5A) cells and
HCT116 (Figure 5B). These results confirm our findings in
HT29 cells and, moreover, suggest a general regulation of
GSK-3a/b phosphorylation by NT in colon cancer cells that
possess NTR.
Treatment with NT or GSK-3a/ Inhibition Increases
Cyclin D1 Expression in HT29 Cells
Cyclin D1 protein, which plays a critical role in intestinal
epithelial cell growth and carcinogenesis [41–43], is stabi-
lized by GSK-3b inhibition [44–46]. To investigate whether
Figure 4. Inhibition of PKC1 blocked NT-induced GSK-3a/ phosphorylation in HT29 cells. (A) HT29 cells were serum-starved for 24 hours; cells were pretreated
with Go¨6976 (which inhibits PKCa, and PKC1) for 30 minutes, followed by treatment with NT (100 nM) for 20 minutes. Total protein was extracted from cells and
resolved by SDS-PAGE, transferred to PVDF membranes, and probed with anti –phospho-GSK-3a/ antibody; membranes were stripped and reprobed with anti –
GSK-3a/ antibody. (B) Western analysis of PKCa and PKC1 expression levels in HT29 cells. Cell lysates, before and after PMA (1 M) treatment for 24 hours,
were fractionated through 10% polyacrylamide gels and transferred to PVDF membranes. Membranes were probed with antibodies to PKCa, PKC1, and -actin
(loading control), and the final detection was carried out by ECL. (C) HT29 cells were pretreated with PMA (1 M) for 24 hours followed by treatment with 100 nM
NT for 20 minutes. Total protein was extracted from cells and resolved by SDS-PAGE, transferred to PVDF membranes, and probed with anti –phospho-GSK-3a/
antibody; membranes were stripped and reprobed with anti –GSK-3a/ antibody. (D) HT29 cells were serum-starved for 24 hours and then pretreated with
LY379196 (which inhibits PKC1) for 30 minutes, followed by treatment with NT (100 nM) for 20 minutes. Total protein was extracted from cells and resolved by
SDS-PAGE, transferred to PVDF membranes, and probed with anti –phospho-GSK-3a/ antibody; membranes were stripped and reprobed with anti –GSK-3a/
antibody. Representative data from three separate experiments are shown.
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NT-mediated GSK-3 phosphorylation is related to increased
cyclin D1 levels, we first determined whether NT treatment
increases cyclin D1 expression in HT29 cells. As shown in
Figure 6 (upper panel ), cyclin D1 expression was increased
at 4 hours after the addition of NT. Subsequently, we used
SB216763, a potent inhibitor of GSK-3a and GSK-3b, in an
ATP-competitive manner [47] to determine whether inhibition
of GSK-3 leads to increased cyclin D1 expression levels in
HT29 cells. As expected, treatment with SB216763 increased
cyclin D1 expression in HT29 cells (Figure 6, lower panel).
Discussion
GSK-3–mediated signaling is implicated in multiple biologic
processes, including embryonic development, cell differenti-
ation, apoptosis, and insulin response, by the phosphoryla-
tion of a broad range of substrates, including several critical
transcription factors (e.g., c-Myc, c-Jun, and c-Myb, and the
translation factor eIF2B) [30,31]. GSK-3 phosphorylates
b-catenin (at Ser-33, Ser-37, and Thr-41) and leads to its
ubiquitination and proteasomal degradation, mimicking the
effects of Wnt signaling activation [48]. The activation of
canonical Wnt signaling stabilizes cytosolic b-catenin, result-
ing in its translocation to the nucleus and the stimulation of
T-cell factor/lymphoid enhancer factor and target genes such
as cyclin D1 [49]. Recently, we have shown that GSK-3 is
involved in the regulation of TRAIL expression in human
colon cancer cells [50], and inhibition of GSK-3 inhibits in-
testinal cell differentiation (Wang et al., unpublished data).
GSK-3 is rapidly phosphorylated at Ser-21 in GSK-3a or at
Ser-9 in GSK-3b, resulting in the inhibition of GSK-3 kinase
activity [51,52]. Numerous stimuli lead to the inactivation of
GSK-3 through S9/S21 phosphorylation, including growth
factors such as epidermal growth factor and platelet-derived
growth factor, which stimulate theGSK-3–inactivating kinase
p90RSK through MAP kinases [37], activators of p70 ribo-
somal S6 kinase (p70S6K) [53], and activators of cAMP-
activated protein kinase A (PKA) [54] and PKC [18,19].
Consistent with its position downstream of the PI3-kinase–
PKB/Akt pathway, GSK-3 activity suppresses cell prolifera-
tion and survival [28,29]. In striking contrast, virtually nothing
is known about the regulation of GSK-3 phosphorylation at
serine residues by GI growth hormones that stimulate in-
testinal growth. In the present study, we show that the GI
hormone NT induces a rapid increase in GSK-3 phosphory-
lation. Our results also indicate that PKC activation increases
the phosphorylation of GSK-3b, implying a pathway that
may be involved in physiological functions mediated by NT.
NT plays an important role in the stimulation of cell
proliferation through multiple signaling pathways, including
the activation of the ERK1/2 [12–14], PKC, and PI3-kinase/
Akt pathways in some cells [15–17]. Although we show that
NT stimulated ERK1/2, Akt, and PKC, only the inhibition of
PKC blocked NT-mediated GSK-3b phosphorylation. In
agreement with our results, Vilimek and Duronio [55] showed
that cytokine-stimulated phosphorylation of GSK-3 is depen-
dent on PKC, but not on PI3-kinase/Akt. These data suggest
that NT, similar to cytokines, acts on GSK-3 through PKC
activation and is independent of the PI3-kinase/Akt pathway.
We have shown that NT activates PKC, resulting in the
phosphorylation of GSK-3. Bozou et al. [24] reported that NT
only weakly stimulates PKC activity in HT29 cells. In this
study, PKC activation was assessed indirectly by measuring
epidermal growth factor binding to HT29 cells. We showed
that NTstimulated obvious PKCa and PKCb1 activation. The
differences noted in activation may be a result of the different
methods used for PKC activity assays. We assessed PKC
activity directly by immunoprecipitation using anti-PKCa or
anti-PKCb1 antibody followed by in vitro kinase assay using
MBP as substrate.
Our results indicate that the PKC inhibitors Go¨6976 and
LY379196 (which selectively inhibit either PKCa and PKCb1,
respectively) [56,57] or downregulation of PKCa and PKCb1
(by prolonged PMA treatment) blocked NT-mediated GSK-3b
(but not GSK-3a) phosphorylation. These findings suggest a
Figure 5. NT induces GSK-3a/ phosphorylation in SW480 and HCT116 cells.
SW480 (A) or HCT116 (B) cells were serum-starved for 24 hours. Cells were
treated with NT (100 nM) for 20 minutes. Total protein was extracted from cells
and resolved by SDS-PAGE, transferred to PVDF membranes, and probed
with anti – phospho-GSK-3a/ antibody; membranes were stripped and
reprobed with anti –GSK-3a/ antibody. Signals from three separate experi-
ments were quantitated densitometrically and expressed as fold changes with
respect to total GSK-3a and PKC, respectively.
Figure 6. Inhibition of GSK-3 increases cyclin D1 expression in HT29 cells.
HT29 cells were serum-starved for 24 hours, followed by treatment with NT or
a specific GSK-3 inhibitor, SB216763, for 4 hours. Protein was extracted, and
cyclin D1 expression was assessed by Western blot analysis. Membranes
were stripped and reprobed with antiactin. Representative data from three
separate experiments are shown.
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role for PKCb1 in the NT-mediated phosphorylation of GSK-
3b; NT-mediated GSK-3a phosphorylation likely occurs
through other kinase(s). Although it was noted that PKCa
and PKCb1 phosphorylate GSK-3b and GSK-3a [19], our
results are largely consistent with a previous report by Goode
et al. [18]. In this study, the effect of individual PKC isoforms
on GSK-3 kinase activity in vitro was assessed. PKCa and
PKCb1 were among the PKC isoforms shown to phosphory-
late GSK-3b, but not GSK-3a; however, the kinase that
phosphorylates GSK-3a was not identified [10]. GSK-3a
and GSK-3b are conserved with high homology within their
kinase domains (98% identity), but only at 36% identity in the
last 76 C-terminal residues [32]. GSK-3a and GSK-3b, al-
though structurally similar, are not functionally identical. This
became obvious in the ablation of the GSK-3b isoform in
mice, which resulted in an embryonic lethal phenotype due to
severe liver degeneration during midgestation [33]. The
inability of GSK-3a to rescue GSK-3b–null mice indicates
that a degenerative liver phenotype arises specifically from
the loss of the b isoform. The phenotype ofmice lackingGSK-
3a has not yet been reported. It is interesting to speculate on
a potentially unique role of GSK-3a in NT-mediated cellular
responses. Future studies will assess the kinase(s) that
contributes to NT-mediated GSK-3a phosphorylation.
Several studies have shown that NT stimulates intestinal
cell growth [6–8,58]; however, the molecular mechanisms by
which NT promotes cell proliferation and growth are largely
undefined. In the present study, we showed that NT treatment
or GSK-3 inhibition induced cyclin D1 expression. GSK-3 is a
well-known regulator of cyclin D1 protein [59,60]. Phosphor-
ylation of cyclin D1 on Thr-286 by GSK-3b results in the
exclusion of cyclin D1 from the nucleus to initiate its protea-
somal degradation [45]. Conversely, inactivated GSK-3b
results in the suppression of cyclin D1 phosphorylation at
Thr-286, thereby suppressing cyclin D1 degradation. Inhibi-
tion of GSK-3b stabilizes b-catenin expression, catalyzes its
localization to the nucleus, and upregulates the downstream
target gene cyclin D1 [59]. Extracellular mitogens promote
cellular proliferation through receptor-mediated signaling
circuitry, which ultimately converges on the cell cycle ma-
chine, and D-type cyclins function as critical sensors of these
signals. During the G1 phase, cyclin D1 accumulates and
assembles with either cyclin-dependent kinase in response
tomitogenic growth factors. The active cyclin D1 holoenzyme
promotes G1 progression by the inactivation of the growth-
suppressive properties of the retinoblastoma protein and
by virtue of its ability to titrate CDK inhibitors such as
p27Kip1 and p21Cip1 [42]. Titration of p27Kip1 and p21Cip1, in
turn, facilitates the activation of the cyclin E/CDK2 complex
and its subsequent entry and progression through the DNA
synthetic (S) phase of the cell cycle. Given the critical roles of
cyclin D1 in cell cycle progression and cell growth, our results
provide a novel mechanism by which NT/GSK-3 may pro-
mote the proliferation and growth of colon cancer cells.
In conclusion, our results indicate that GSK-3 activity can
be modulated by growth factors, such as NT, that work
through the activation of PKC. Our present study under-
scores multiple levels of cross-talk between signaling cas-
cades that regulate functionally critical molecules such as
GSK-3. Moreover, our findings suggest that the NT-mediated
proliferation of cancer cells possessing high-affinity NTRmay
be mediated, in part, through the modulation of GSK-3
phosphorylation by PKC signaling molecules.
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